$29.7 Million is the total value of ARCH Venture Management, LLC's 4 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SYRS | Sell | SYROS PHARMACEUTICALS INC | $4,264,000 | -76.5% | 400,000 | -86.9% | 14.34% | -53.2% |
| KURA | Sell | KURA ONCOLOGY INC | $3,363,000 | -16.8% | 206,307 | -49.2% | 11.31% | +65.7% |
| IOTS | Exit | ADESTO TECHNOLOGIES CORP | $0 | – | -1,876,511 | -100.0% | -35.45% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| RUBIUS THERAPEUTICS, INC. | 12 | Q3 2022 | 65.5% |
| ERASCA, INC. | 11 | Q2 2024 | 28.4% |
| VERVE THERAPEUTICS, INC. | 11 | Q2 2024 | 33.2% |
| SINGULAR GENOMICS SYSTEMS, INC. | 10 | Q1 2024 | 4.6% |
| EQRX, INC. | 8 | Q3 2023 | 52.4% |
| DENALI THERAPEUTICS, INC. | 8 | Q1 2024 | 28.6% |
| CHIASMA INC | 8 | Q3 2020 | 25.7% |
| UNITY BIOTECHNOLOGY, INC. | 8 | Q2 2024 | 2.1% |
| KURA ONCOLOGY INC | 7 | Q2 2020 | 27.6% |
| KARUNA THERAPEUTICS, INC. | 6 | Q1 2023 | 52.8% |
View ARCH Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-15 |
View ARCH Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.